Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) EBITDA (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed EBITDA for 15 consecutive years, with -$5.7 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 47.23% to -$5.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$15.3 million through Dec 2025, down 4.1% year-over-year, with the annual reading at -$15.3 million for FY2025, 4.1% down from the prior year.
  • EBITDA for Q4 2025 was -$5.7 million at Plus Therapeutics, down from -$4.5 million in the prior quarter.
  • The five-year high for EBITDA was -$1.5 million in Q2 2023, with the low at -$5.7 million in Q4 2025.
  • Average EBITDA over 5 years is -$3.8 million, with a median of -$3.8 million recorded in 2024.
  • The sharpest move saw EBITDA plummeted 150.64% in 2021, then soared 70.9% in 2023.
  • Over 5 years, EBITDA stood at -$3.5 million in 2021, then plummeted by 59.25% to -$5.6 million in 2022, then soared by 30.76% to -$3.9 million in 2023, then fell by 1.09% to -$3.9 million in 2024, then tumbled by 47.23% to -$5.7 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$5.7 million, -$4.5 million, and -$1.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.